Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study

References

• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–8. doi:10.1038/NRC3239.
   PubMed Web of Science ®Google Scholar
• Liang M, Schwickart M, Schneider AK, Vainshtein I, Del Nagro C, Standifer N, Roskos LK. Receptor occupancy assessment by flow cytometry as a pharmacodynamic biomarker in biopharmaceutical development. Cytometry B Clin Cytom. 2016;90(2):117–27. doi:10.1002/CYTO.B.21259.
   PubMed Web of Science ®Google Scholar
• Sternebring O, Alifrangis L, Christensen TF, Ji H, Hegelund AC, Högerkorp CM. A weighted method for estimation of receptor occupancy for pharmacodynamic measurements in drug development. Cytometry B Clin Cytom. 2016;90(2):220–29. doi:10.1002/CYTO.B.21277.
   PubMed Web of Science ®Google Scholar
• Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027–34. doi:10.1084/JEM.192.7.1027.
   PubMed Web of Science ®Google Scholar
• Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004;173(2):945–54. doi:10.4049/JIMMUNOL.173.2.945.
   PubMed Web of Science ®Google Scholar
• Quan L, Chen X, Liu A, Zhang Y, Guo X, Yan S, Liu Y. PD-1 blockade can restore functions of T-cells in epstein-barr virus-positive diffuse large B-Cell lymphoma in vitro. PLoS One. 2015;10(9). doi:10.1371/JOURNAL.PONE.0136476.
   Web of Science ®Google Scholar
• Hazarika M, Chuk MK, Theoret MR, Mushti S, He K, Weis SL, Putman AH, Helms WS, Cao X, Li H, et al. U.S. FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab. Clin Cancer Res. 2017;23(14):3484–88. doi:10.1158/1078-0432.CCR-16-0712.
   PubMed Web of Science ®Google Scholar
• Kazandjian D, Suzman DL, Blumenthal G, Mushti S, He K, Libeg M, Keegan P, Pazdur R. FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy. Oncologist. 2016;21(5):634–42. doi:10.1634/THEONCOLOGIST.2015-0507.
   PubMed Web of Science ®Google Scholar
• Xu JX, Maher VE, Zhang L, Tang S, Sridhara R, Ibrahim A, Kim G, Pazdur R. FDA approval summary: nivolumab in advanced renal cell carcinoma after anti-angiogenic therapy and exploratory predictive biomarker analysis. Oncologist. 2017;22(3):311–17. doi:10.1634/THEONCOLOGIST.2016-0476.
   PubMed Web of Science ®Google Scholar
• Kasamon YL, de Claro RA, Wang Y, Shen YL, Farrell AT, Pazdur R. FDA approval summary: nivolumab for the treatment of relapsed or progressive classical hodgkin lymphoma. The Oncologist. 2017;22(5):585–91. doi:10.1634/THEONCOLOGIST.2017-0004.
   PubMed Web of Science ®Google Scholar
• Agrawal S, Feng Y, Roy A, Kollia G, Lestini B. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. Journal for ImmunoTherapy of Cancer. 2016;4(1). doi:10.1186/S40425-016-0177-2.
   PubMedGoogle Scholar
• OPDIVO (Nivolumab). Label.; 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/125554s112lbl.pdf.
   Google Scholar
• Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28(19):3167–75. doi:10.1200/JCO.2009.26.7609.
   PubMed Web of Science ®Google Scholar
• OPDIVO (Nivolumab). Assessment Report.; 2015. https://www.ema.europa.eu/en/documents/assessment-report/opdivo-epar-public-assessment-report_en.pdf.
   Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–54. doi:10.1056/NEJMOA1200690.
   PubMed Web of Science ®Google Scholar
• Pluim D, Ros W, Miedema IHC, Beijnen JH, Schellens JHM. Multiparameter flow cytometry assay for quantification of immune cell subsets, PD-1 expression levels and pd-1 receptor occupancy by nivolumab and pembrolizumab. Cytometry A. 2019;95(10):1053–65. doi:10.1002/CYTO.A.23873.
   PubMed Web of Science ®Google Scholar
• Awan M, Buriak I, Fleck R, Fuller B, Goltsev A, Kerby J, Lowdell M, Mericka P, Petrenko A, Petrenko Y, et al. Dimethyl sulfoxide: a central player since the Dawn of cryobiology, is efficacy balanced by toxicity? Regen Med. 2020;15(3):1463–91. doi:10.2217/RME-2019-0145.
   PubMed Web of Science ®Google Scholar
• Fu J, Wang F, Dong LH, Xing MJ, Cheng X, Wei S, Xu JZ, Han M, Dong K, Song HF. Receptor occupancy measurement of anti-PD-1 antibody drugs in support of clinical trials. Bioanalysis. 2019;11(14):1347–58. doi:10.4155/BIO-2019-0090.
   PubMed Web of Science ®Google Scholar
• He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30(8):660–69. doi:10.1038/S41422-020-0343-4.
   PubMed Web of Science ®Google Scholar
• Yanagihara T, Tanaka K, Matsumoto K. A measuring method for occupancy of immune checkpoint inhibitors in the cell surface. Biochem Biophys Res Commun. 2020;527(1):213–17. doi:10.1016/J.BBRC.2020.04.122.
   PubMed Web of Science ®Google Scholar
• Das R, Verma R, Sznol M, Boddupalli CS, Gettinger SN, Kluger H, Callahan M, Wolchok JD, Halaban R, Dhodapkar MV, et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol. 2015;194(3):950–59. doi:10.4049/JIMMUNOL.1401686.
   PubMed Web of Science ®Google Scholar
• Vainshtein I, Schneider AK, Sun B, Schwickart M, Roskos LK, Liang M. Multiplexing of receptor occupancy measurements for pharmacodynamic biomarker assessment of biopharmaceuticals. Cytometry B Clin Cytom. 2016;90(2):128–40. doi:10.1002/CYTO.B.21319.
   PubMed Web of Science ®Google Scholar
• Powderly J, Spira A, Kondo S, Doi T, Luke JJ, Rasco D, Gao B, Tanner M, Cassier PA, Gazzah A, et al. model informed dosing regimen and phase i results of the anti‐PD‐1 antibody budigalimab (ABBV‐181). Clin Transl Sci. 2021;14(1):277. doi:10.1111/CTS.12855.
   PubMed Web of Science ®Google Scholar
• Mo H, Huang J, Xu J, Chen X, Wu D, Qu D, Wang X, Lan B, Wang X, Xu J, et al. Safety, anti-tumour activity, and pharmacokinetics offixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: adose-escalation, phase 1 study. Br J Cancer. 2018;119(5):538. doi:10.1038/S41416-018-0100-3.
   PubMed Web of Science ®Google Scholar
• Advani R, Flinn I, Popplewell L, Forero A, Bartlett NL, Ghosh N, Kline J, Roschewski M, LaCasce A, Collins GP, et al. cd47 blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma. N Engl J Med. 2018;379(18):1711–21. doi:10.1056/NEJMOA1807315.
   PubMed Web of Science ®Google Scholar
• Chen JY, McKenna KM, Choi TS, Duan J, Brown L, Stewart JJ, Sompalli K, Vyas P, Schrier S, Majeti R, et al. RBC-Specific CD47 Pruning confers protection and underlies the transient anemia in patients treated with anti-CD47 Antibody 5F9. Blood. 2018;132(Supplement 1):2327–2327. doi:10.1182/BLOOD-2018-99-115674.
   Google Scholar
• Bajaj G, Wang X, Agrawal S, Gupta M, Roy A, Feng Y. Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacometrics Syst Pharmacol. 2017;6(1):58–66. doi:10.1002/PSP4.12143.
   PubMedGoogle Scholar
• Bell GI. Models for the specific adhesion of cells to cells. Science. 1978;200(4342):618–27. doi:10.1126/SCIENCE.347575.
   PubMed Web of Science ®Google Scholar
• Kaufman EN, Jain RK. Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays. Cancer Res. 1992;52:4157–67.
   PubMed Web of Science ®Google Scholar
• Li K, Cheng X, Tilevik A, Davis SJ, Zhu C. In situ and in silico kinetic analyses of programmed cell death-1 (PD-1) receptor, programmed cell death ligands, and B7-1 protein interaction network. J Biol Chem. 2017;292(16):6799–809. doi:10.1074/JBC.M116.763888.
   PubMed Web of Science ®Google Scholar
• Lassman ME, Chappell DL, McAvoy T, Cheng A, de Alwis Dp, Pruitt SK, Laterza OF, Li C, Stoch A, Mayawala K, et al. Experimental Medicine Study to Measure Immune Checkpoint Receptors PD-1 and GITR Turnover Rates In Vivo in Humans.Clin Pharmacol Ther. 2021;109(6):1575–82. doi:10.1002/CPT.2129
   PubMed Web of Science ®Google Scholar
• Chapman EH, Kurec AS, Davey FR. Cell volumes of normal and malignant mononuclear cells. J Clin Pathol. 1981;34(10):1083–90. doi:10.1136/JCP.34.10.1083.
   PubMed Web of Science ®Google Scholar
• Junker F, Gulati P, Wessels U, Seeber S, Stubenrauch KG, Codarri-Deak L, Markert C, Klein C, Teixeira PC, Kao H. A human receptor occupancy assay to measure anti-PD-1 binding in patients with prior anti-PD-1. Cytometry A. 2021;99(8):832–43. doi:10.1002/CYTO.A.24334.
   PubMed Web of Science ®Google Scholar
• Metelkin E. Heta compiler: a software tool for the development of large-scale QSP models and compilation into simulation formats. J Open Source Softw. 2021;6(67):3708. doi:10.21105/JOSS.03708.
   Google Scholar
• Gizzatkulov NM, Goryanin II, Metelkin EA, Mogilevskaya EA, Peskov KV, Demin OV. DBSolve Optimum: a software package for kinetic modeling which allows dynamic visualization of simulation results. BMC Syst Biol. 2010;4:4. doi:10.1186/1752-0509-4-109.
   PubMed Web of Science ®Google Scholar